Y mAbs Therapeutics — Company Overview, News & Financial Data
Y-mAbs Therapeutics focuses on developing antibody-based therapies for cancer and rare diseases to improve patient outcomes.
Y mAbs Therapeutics
Company profile
About Y mAbs Therapeutics
Y-mAbs Therapeutics (NASDAQ:YMAB) is a biopharmaceutical company focused on the development and commercialization of novel antibody-based therapies for the treatment of cancer and rare diseases. Their operations span from early-stage research to the commercialization of their products, aiming to improve patient outcomes with cutting-edge treatments. Y mAbs Therapeutics is dedicated to advancing a diverse pipeline of therapeutic candidates, including projects targeting pediatric cancers and other life-threatening conditions. Their objective is to translate groundbreaking scientific research into transformative therapies for patients who currently have limited treatment options, emphasizing a commitment to innovation and patient care in the medical field.
Snapshot
2015Year founded
109Employees
New York, United StatesHead office
Loading Map...
Global footprint
Operations
All Locations
New York City, US
Products and/or services of Y mAbs Therapeutics
- DANYELZA, an FDA-approved treatment for pediatric and adult patients with relapsed or refractory high-risk neuroblastoma in combination with granulocyte-macrophage colony-stimulating factor.
- Omburtamab, an investigational radioimmunotherapy under development for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma and other potential indications.
- GD2-GD3 Vaccine, an investigational cancer vaccine aimed at stimulating the immune system to attack neuroblastoma cells, currently in early clinical development.
- naxitamab, an investigational GD2-directed antibody being evaluated for various types of cancers, including osteosarcoma and other solid tumors, in combination with other therapies.
- SADA technology, a proprietary drug development platform designed to create next-generation antibody-drug conjugates and radioimmunotherapies with potential applications across multiple cancer types.
- GD2-BiTE, an investigational bispecific T-cell engager targeting GD2-positive cancers, leveraging the immune system to destroy cancer cells, currently in pre-clinical development.
Y mAbs Therapeutics executive team
- Mr. Michael RossiCEO, President & Director
- Mr. Thomas GadFounder, Chief Business Officer & Vice Chairman
- Mr. Peter P. Pfreundschuh CPAExecutive VP, CFO & Treasurer
- Mr. Joris Wiel Jan WilmsSenior VP & COO
- Dr. Torben Lund-Hansen M.Sc., Ph.D.Senior VP & CTO
- Ms. Courtney DuganVP & Head of Investor Relations
- Mr. John W. LaRocca Esq.Senior VP, General Counsel, Secretary & Chief Legal Officer
- Dr. Norman D. LaFrance FACNP, FACP, M.D.Chief Development Officer & Chief Medical Officer
- Mr. Doug GentilcoreSenior VP & Head of DANYELZA Business Unit
- Ms. Natalie TuckerSenior VP & Radiopharmaceutical Business Unit Head
GET YOUR GRAFA EDGE NOW
Sign up free to follow this company
We'll switch on a 30-day Edge trial as a welcome gift